Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - Qilu Pharmaceutical

Next Previous
X
Search
Drug Profile

Bevacizumab biosimilar - Qilu Pharmaceutical

Alternative Names: Ankeda; QL 1101

Latest Information Update: 12 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Developer Qilu Pharmaceutical; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Aug 2020 Qilu Pharmaceutical and Shanghai Junshi Bioscience plan a phase II BEVTOR trial for Colorectal cancer (Combination therapy, Inoperable/unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in China (IV) (NCT04527068)
  • 09 Dec 2019 Preregistration for Non-small cell lung cancer (First-line therapy, Late-stage disease) in China (IV) before December 2019
  • 09 Dec 2019 Preregistration for Non-small cell lung cancer (In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (IV) before December 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top